Literature DB >> 15210309

Analysis of a three-way race between tumor growth, a replication-competent virus and an immune response.

Joseph T Wu1, David H Kirn, Lawrence M Wein.   

Abstract

Replication-competent viruses have the potential to overcome the delivery barrier in tumors that has plagued traditional gene-therapy approaches to cancer treatment. However, recent clinical data suggests that a cytokine-based immune response against the virus-infected tumor cells may severely limit the efficacy of the replication-competent approach. This paper generalizes our earlier spatial model to incorporate an immune response against the infected tumor cells. An approximate but accurate condition is derived for the virus-if uniformly injected throughout the tumor-to eradicate the tumor in the presence of the immune response. To validate the model using clinical data describing the temporal interaction of tumor necrosis factor and free virus in the plasma, we needed the immune response to be time-delayed and experience either saturated stimulation or second-order clearance. The resulting estimates of some unknown parameters provide some implications for the delivery of treatment.

Entities:  

Mesh:

Year:  2004        PMID: 15210309     DOI: 10.1016/j.bulm.2003.08.016

Source DB:  PubMed          Journal:  Bull Math Biol        ISSN: 0092-8240            Impact factor:   1.758


  14 in total

1.  Perfusion Pressure Is a Critical Determinant of the Intratumoral Extravasation of Oncolytic Viruses.

Authors:  Amber Miller; Rebecca Nace; Camilo Ayala-Breton C; Michael Steele; Kent Bailey; Kah Whye Peng; Stephen J Russell
Journal:  Mol Ther       Date:  2015-12-09       Impact factor: 11.454

2.  In Vivo Estimation of Oncolytic Virus Populations within Tumors.

Authors:  Mi-Yeon Jung; Chetan P Offord; Matthew K Ennis; Iris Kemler; Claudia Neuhauser; David Dingli
Journal:  Cancer Res       Date:  2018-08-16       Impact factor: 12.701

3.  The competitive dynamics between tumor cells, a replication-competent virus and an immune response.

Authors:  Youshan Tao; Qian Guo
Journal:  J Math Biol       Date:  2005-03-15       Impact factor: 2.259

4.  Dynamics of melanoma tumor therapy with vesicular stomatitis virus: explaining the variability in outcomes using mathematical modeling.

Authors:  D M Rommelfanger; C P Offord; J Dev; Z Bajzer; R G Vile; D Dingli
Journal:  Gene Ther       Date:  2011-09-15       Impact factor: 5.250

5.  Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model.

Authors:  Elizabeth K Hellums; James M Markert; Jacqueline N Parker; Bin He; Bernard Perbal; Bernard Roizman; Richard J Whitley; Catherine P Langford; Suman Bharara; G Yancey Gillespie
Journal:  Neuro Oncol       Date:  2005-07       Impact factor: 12.300

Review 6.  In silico cancer modeling: is it ready for prime time?

Authors:  Thomas S Deisboeck; Le Zhang; Jeongah Yoon; Jose Costa
Journal:  Nat Clin Pract Oncol       Date:  2008-10-14

7.  Dynamics of multiple myeloma tumor therapy with a recombinant measles virus.

Authors:  D Dingli; C Offord; R Myers; K-W Peng; T W Carr; K Josic; S J Russell; Z Bajzer
Journal:  Cancer Gene Ther       Date:  2009-06-05       Impact factor: 5.987

8.  Mathematical modeling of tumor therapy with oncolytic viruses: regimes with complete tumor elimination within the framework of deterministic models.

Authors:  Artem S Novozhilov; Faina S Berezovskaya; Eugene V Koonin; Georgy P Karev
Journal:  Biol Direct       Date:  2006-02-17       Impact factor: 4.540

Review 9.  Oncolytic viruses and immunity.

Authors:  Shyambabu Chaurasiya; Nanhai G Chen; Yuman Fong
Journal:  Curr Opin Immunol       Date:  2018-03-16       Impact factor: 7.268

10.  Mathematical model for radial expansion and conflation of intratumoral infectious centers predicts curative oncolytic virotherapy parameters.

Authors:  Kent Bailey; Amber Kirk; Shruthi Naik; Rebecca Nace; Michael B Steele; Lukkana Suksanpaisan; Xing Li; Mark J Federspiel; Kah-Whye Peng; David Kirk; Stephen J Russell
Journal:  PLoS One       Date:  2013-09-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.